Literature DB >> 2965631

Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man.

A Morice1, J Pepke-Zaba, E Loysen, R Lapworth, M Ashby, T Higenbottam, M Brown.   

Abstract

1. The effects of low dose infusion of atrial natriuretic peptide (ANP) were observed in double-blind, placebo-controlled study in six fluid-loaded volunteers. After baseline observations, hourly increments of 0.4, 2 and 10 pmol min-1 kg-1 were infused with continuous observation of heart rate, blood pressure and cardiac output. Plasma ANP, aldosterone, and catecholamines, and urinary volume and sodium excretion, were estimated at half-hourly intervals. 2. ANP infusion resulted in an increase of 35, 98 and 207% in urinary sodium excretion and of 10, 20 and 71% in urinary volume when compared with placebo. Plasma ANP was markedly elevated above placebo levels only during infusion of 10 pmol of ANP min-1 kg-1. 3. No change in heart rate of blood pressure was noted during the study, but a significant fall in stroke volume index was observed during active treatment. Plasma levels of aldosterone and catecholamines were not significantly different on the 2 treatment days. 4. The potent natriuretic and diuretic effects of this peptide at plasma concentrations not significantly elevated from physiological suggest a hormonal role for ANP in the homoeostasis of salt and water balance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965631     DOI: 10.1042/cs0740359

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  7 in total

1.  The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans.

Authors:  Aruna R Natarajan; Gilbert M Eisner; Ines Armando; Shaunagh Browning; John C Pezzullo; Lauren Rhee; Mustafa Dajani; Robert M Carey; Pedro A Jose
Journal:  J Am Soc Nephrol       Date:  2015-05-14       Impact factor: 10.121

2.  Effects of insulin on kidney function and sodium excretion in healthy subjects.

Authors:  P Skøtt; O Hother-Nielsen; N E Bruun; J Giese; M D Nielsen; H Beck-Nielsen; H H Parving
Journal:  Diabetologia       Date:  1989-09       Impact factor: 10.122

3.  Haemodynamic effects of atrial natriuretic peptide in hypoxic chronic obstructive pulmonary disease.

Authors:  T K Rogers; W Sheedy; J Waterhouse; P Howard; A H Morice
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

Review 4.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

5.  Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

Authors:  Wei-Chi Liao; Ole Vesterqvist; Carol Delaney; Mohammed Jemal; Irene Ferreira; Neville Ford; Brian Swanson; Howard Uderman
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

6.  Exercise increases the release of atrial natriuretic peptide in heart transplant recipients.

Authors:  J Pepke-Zaba; T W Higenbottam; A Morice; A T Dinh-Xuan; A E Raine; J Wallwork
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Changes in atrial natriuretic peptide concentrations during intravenous saline infusion in hypoxic cor pulmonale.

Authors:  A G Stewart; P A Bardsley; S V Baudouin; J C Waterhouse; J S Thompson; A H Morice; P Howard
Journal:  Thorax       Date:  1991-11       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.